Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie CDR (Cad Hedged) (ABBV.TO)

Abbvie CDR (Cad Hedged) (ABBV.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Abbvie CDR (Cad Hedged) 1 North Waukegan Road North Chicago IL 60064-6400 USA

https://www.abbvie.com P: 847-932-7900

Sector:

Medical

Description:

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Key Statistics

Overview:

Market Capitalization, $K 512,647,843
Shares Outstanding, K 16,712,880
% of Institutional Shareholders 0.12%

Financials:

Annual Sales, $ 61,160 M
Annual Net Income, $ 4,226 M
Last Quarter Sales, $ 16,618 M
Last Quarter Net Income, $ 1,816 M

Growth:

1-Year Return -0.34%
3-Year Return 22.94%
5-Year Return 0.00%
5-Year Revenue Growth 5.95%
5-Year Earnings Growth -2.72%

Per-Share Information:

Most Recent Earnings 0.11 on 02/04/26
Next Earnings Date N/A
Earnings Per Share ttm 0.25
EPS Growth vs. Prev Qtr 920.00%
EPS Growth vs. Prev Year -0.01%
Annual Dividend & Yield (Paid) 0.67 (3.22%)
Annual Dividend & Yield (Fwd) 0.97 (3.22%)
Most Recent Dividend 0.242 on 04/15/26
Next Ex-Dividends Date 04/15/26
Dividend Payable Date 05/25/26
Dividend Payout Ratio 266.01%

ABBV.TO Ratios

Ratio
Price/Earnings ttm 84.07
Price/Earnings forward 13.70
Price/Earnings to Growth 0.47
Return-on-Equity % 15,221.82%
Return-on-Assets % 3.11%
Profit Margin % 6.84%
Debt/Equity N/A
Price/Sales 5.78
Price/Book N/A
Book Value/Share -0.27

ABBV.TO Dividends

Date Value
04/15/26 $0.2421
01/16/26 $0.2378
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.